Aligos Therapeutics (ALGS) EBITDA Margin (2019 - 2026)
Aligos Therapeutics' EBITDA Margin was -762.90% in Q3 2026, up 3037.51 percentage points from -3800.40% a year earlier.
Aligos Therapeutics (ALGS) EBITDA Margin (2019 - 2026) Analysis & Trends
On a trailing twelve-month basis, Aligos Therapeutics' EBITDA Margin was -1224.00% through Sep 30, 2026, up 2047.33 percentage points year-over-year; for FY2025, it was -3982.39%, down 1541.87 percentage points from FY2024.
- EBITDA Margin has now declined for three consecutive years, though with a five-year change of +2969.29 percentage points (FY2020 to FY2025).
- In earlier years, EBITDA Margin was -2440.52% in FY2024 (-1513.90 pp), -926.61% in FY2023 (-241.53 pp), -685.08% in FY2022 (+2189.48 pp) and -2874.56% in FY2021 (+4077.12 pp).
- The Q3 2026 figure marks the highest quarterly EBITDA Margin since Q2 2023.
- Compared with a year earlier, EBITDA Margin was higher in three of the last seven quarters, with an average year-over-year change of -1130.21 percentage points.
- The best year-over-year quarter for EBITDA Margin over five years was Q4 2022 (a gain of 9517.17 percentage points); the worst was Q4 2025 (a drop of 9415.82 percentage points).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 42.49% |
| 10 | Aligos Therapeutics | 21.97 Mn | -314.86 Mn | - | -762.90% |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -762.90% |
| Mar 31, 2026 | -939.33% |
| Dec 31, 2025 | -12,771.60% |
| Sep 30, 2025 | -3,800.40% |
| Jun 30, 2025 | -1,892.95% |
| Mar 31, 2025 | -6,123.15% |
| Dec 31, 2024 | -3,355.78% |
| Sep 30, 2024 | -1,586.48% |
| Jun 30, 2024 | -2,461.26% |
| Mar 31, 2024 | -3,133.43% |
| Dec 31, 2023 | -1,274.12% |
| Sep 30, 2023 | -871.45% |
| Jun 30, 2023 | -436.45% |
| Mar 31, 2023 | -906.62% |
| Dec 31, 2022 | -626.97% |
| Sep 30, 2022 | -449.29% |
| Jun 30, 2022 | -535.96% |
| Mar 31, 2022 | -1,355.78% |
| Dec 31, 2021 | -10,144.14% |
| Sep 30, 2021 | -2,099.41% |
Aligos Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ALGS&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "ALGS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ALGS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();